NovoLog (insulin aspart) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 85 Diseases   38 Trials   38 Trials   1659 News 


«12...234567891011121314»
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    New P3 trial:  FIasp (clinicaltrials.gov) -  Jun 5, 2019   
    P3,  N=40, Recruiting, 
  • ||||||||||  ultra-rapid acting insulin (AT247) / Arecor
    New P1 trial:  AT247, NovoRapid (clinicaltrials.gov) -  May 21, 2019   
    P1,  N=18, Recruiting, 
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Phase classification:  Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes (clinicaltrials.gov) -  May 13, 2019   
    P3,  N=220, Not yet recruiting, 
    Proper enhancement of postprandial endogenous insulin aimed at suppressing postprandial glucose output without stimulating excessive glucose uptake in the periphery is potentially useful for treating diabetes with insulin antibody-induced glycemic instability. Phase classification: P4 --> P3
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Trial termination:  Additional Insulin for Fat and Protein in Children With Diabetes Study (clinicaltrials.gov) -  Apr 25, 2019   
    P4,  N=38, Terminated, 
    Not yet recruiting --> Recruiting | Phase classification: PN/A --> P2/3 | N=20 --> 45 Recruiting --> Terminated; No eligible participants left to approach/ recruit
  • ||||||||||  BIAsp 30 (biphasic insulin aspart 30/70 biosimilar) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Journal, HEOR:  Biphasic insulin aspart 30 treatment for people with type 2 diabetes: a budget impact analysis based in Thailand. (Pubmed Central) -  Apr 17, 2019   
    The NBI per insulin user per year was 33.45 THB (0.97 USD), 67.27 THB (1.96 USD), 101.49 THB (2.95 USD) from year 1 to year 3, respectively Lower rate of hypoglycemia with BIAsp 30 than those treated with BHI 30 generates cost savings resulting in significant deduction in the additional acquisition cost of BIAsp 30. Therefore, the NBI per insulin user per year has become small.
  • ||||||||||  IDegLira (insulin degludec/liraglutide) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA. (Pubmed Central) -  Apr 10, 2019   
    P3
    However, cost of control values were substantially lower with IDegLira when the more stringent target of HbA1c ≤6.5% was used, and when patient-centered outcomes of hypoglycemia risk and impact on weight were included. IDegLira was shown to be a cost-effective treatment vs insulin glargine U100 plus insulin aspart for patients with type 2 diabetes not achieving glycemic targets on basal insulin in the USA.
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Apidra (insulin glulisine) / Sanofi
    Trial completion date, Trial primary completion date:  SWITCH: Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (clinicaltrials.gov) -  Apr 10, 2019   
    P4,  N=400, Recruiting, 
    IDegLira was shown to be a cost-effective treatment vs insulin glargine U100 plus insulin aspart for patients with type 2 diabetes not achieving glycemic targets on basal insulin in the USA. Trial completion date: Nov 2019 --> Jul 2021 | Trial primary completion date: Nov 2019 --> Jul 2021
  • ||||||||||  Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk, Jentadueto (linagliptin+metformin) / Eli Lilly, Boehringer Ingelheim
    Clinical, Journal:  Utilising a milk-based meal replacement programme in a bariatric patient with poorly controlled type 2 diabetes mellitus. (Pubmed Central) -  Apr 9, 2019   
    ...However, 1 year later, despite further weight loss, his HbA1c deteriorated dramatically, requiring introduction of linagliptin and canagliflozin, with good response...Milk-based meal replacement in patients with insulin requiring type 2 diabetes causes rapid and profound reductions in insulin requirements, so rigorous monitoring of glucose levels by patients and their clinicians is necessary. In carefully selected and adequately monitored patients, the response to oral antidiabetic medications may help to differentiate between absolute and relative insulin deficiency.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Analysis of insulin and insulin analogues from dried blood spots by means of LC-HRMS. (Pubmed Central) -  Apr 3, 2019   
    Assay validation demonstrated adequate sensitivity (LOD 0.5 ng/mL for most insulins), as well as precise (< 25 %) and reproducible results for all included target insulins. Additionally, proof-of-principle data were obtained by the analysis of DBS samples obtained from healthy volunteers in non-fasting state as well as a sample from a diabetic volunteer treated with the fast acting analogue insulin Aspart.
  • ||||||||||  NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide. (Pubmed Central) -  Mar 21, 2019   
    Niacinamide mediates the acceleration of initial insulin aspart absorption, and the mechanism of action appears to be multifaceted. Niacinamide increases the initial abundance of insulin aspart monomers and transport of insulin aspart after subcutaneous administration, and also mediates a transient, local vasodilatory effect.
  • ||||||||||  Byetta (exenatide) / AstraZeneca
    Trial completion date, Trial primary completion date:  New Onset Type 1 Diabetes: Role of Exenatide (clinicaltrials.gov) -  Jan 29, 2019   
    P4,  N=20, Recruiting, 
    Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  IDegLira (insulin degludec/liraglutide) / Novo Nordisk
    Enrollment open:  IDegLira HIGH Trial (clinicaltrials.gov) -  Jan 25, 2019   
    P3,  N=140, Recruiting, 
    Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Recruiting
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Apidra (insulin glulisine) / Sanofi
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy) (clinicaltrials.gov) -  Dec 7, 2018   
    P4,  N=15, Terminated, 
    Recruiting --> Completed | Trial completion date: Mar 2019 --> Nov 2018 N=150 --> 15 | Trial completion date: May 2019 --> Nov 2018 | Recruiting --> Terminated | Trial primary completion date: May 2019 --> Nov 2018; Due to "prolonged low participant recruitment"
  • ||||||||||  SAR341402 (insulin aspart rapid-acting biosimilar) / Sanofi
    Trial completion:  Safety Assessment of SAR341402 and NovoLog (clinicaltrials.gov) -  Dec 7, 2018   
    P1,  N=45, Completed, 
    N=150 --> 15 | Trial completion date: May 2019 --> Nov 2018 | Recruiting --> Terminated | Trial primary completion date: May 2019 --> Nov 2018; Due to "prolonged low participant recruitment" Recruiting --> Completed
  • ||||||||||  Kixelle (insulin aspart biosimilar) / Viatris, Biocon
    New P3 trial:  Mylan Insulin Aspart Study (clinicaltrials.gov) -  Nov 30, 2018   
    P3,  N=500, Recruiting, 
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
    Trial completion:  The Insulin-Only Bionic Pancreas Bridging Study (clinicaltrials.gov) -  Nov 27, 2018   
    P2/3,  N=56, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  IDegLira (insulin degludec/liraglutide) / Novo Nordisk
    New P3 trial:  IDegLira HIGH Trial (clinicaltrials.gov) -  Nov 9, 2018   
    P3,  N=140, Not yet recruiting, 
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
    Enrollment closed, Enrollment change:  The Insulin-Only Bionic Pancreas Bridging Study (clinicaltrials.gov) -  Oct 22, 2018   
    P2/3,  N=56, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=88 --> 56
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  SNIFF-Quick: Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart (clinicaltrials.gov) -  Sep 24, 2018   
    P1,  N=30, Recruiting, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Jun 2019 Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019